|
Crohn Disease
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Nevertheless, the significance of the TLR4 299G and TLR9-1237C associations with CD worldwide was confirmed by a meta-analysis test using our datasets and datasets from previously published studies.
|
17914947 |
2007 |
|
Crohn Disease
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Our results provide evidence for genetic interactions between polymorphisms in TLR9 and CD-associated variants in NOD2, IL23R, and DLG5, differentially modulating CD susceptibility.
|
19455129 |
2009 |
|
Crohn Disease
|
0.370 |
Biomarker
|
disease |
BEFREE |
Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease.
|
15928043 |
2005 |
|
Crohn Disease
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Inflamed CD ileal and UC mucosa showed increased IL23A, while only inflamed CD ileal samples showed increased TLR9 mRNA level.
|
30193869 |
2018 |
|
Crohn Disease
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Nineteen functional polymorphisms that alter the NFκB-mediated inflammatory response (TLR2 (rs3804099, rs11938228, rs1816702, rs4696480), TLR4 (rs5030728, rs1554973), TLR9 (rs187084, rs352139), LY96 (MD-2) (rs11465996), CD14 (rs2569190), MAP3K14 (NIK) (rs7222094)), TNF-α signaling (TNFA (TNF-α) (rs361525), TNFRSF1A (TNFR1) (rs4149570), TNFAIP3(A20) (rs6927172)) and other cytokines regulated by NFκB (IL1B (rs4848306), IL1RN (rs4251961), IL6 (rs10499563), IL17A (rs2275913), IFNG (rs2430561)) were associated with response to anti-TNF therapy among patients with CD, UC or both CD and UC (P ⩽ 0.05).
|
24776844 |
2014 |
|
Crohn Disease
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
TLR9 mRNA was equally expressed in colonic mucosa from controls (n = 6) and patients with ulcerative colitis or Crohn's disease disease (n = 13).
|
15996194 |
2005 |
|
Crohn Disease
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
The polymorphisms TLR2 (rs1816702), NFKB1 (rs28362491), TNFRSF1A (rs4149570), IL6R (rs4537545), IL23R (rs11209026) and PTPN22 (rs2476601) were associated with risk of CD and the polymorphisms TLR2 (rs1816702), TLR4 (rs1554973 and rs12377632), TLR9 (rs352139), LY96 (rs11465996), NFKBIA (rs696), TNFA (rs1800629), TNFRSF1A (rs4149570), IL10 (rs3024505), IL23R (rs11209026), PTPN22 (rs2476601) and PPARG (rs1801282) were associated with risk of UC.
|
24971461 |
2014 |
|
Colorectal Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Cell membrane and intracellular expression of toll-like receptor 9 (TLR9) in colorectal cancer and breast cancer cell-lines.
|
28106541 |
2017 |
|
Colorectal Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The expression of TLR9 was measured in different CRC cell lines and cancerous samples by RT-PCR or immunohistochemistry, which showed that high expression of TLR9 was significantly correlated with the tumor metastasis, advanced TNM stage and poor prognosis of patients.
|
30239551 |
2018 |
|
Colorectal Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
With the signal activation, the levels of TLR9 protein raised more in advanced colorectal cancer than in early colorectal cancer.
|
30271180 |
2018 |
|
Colorectal Carcinoma
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
The detection of higher frequencies of the TLR2, TLR4 and/or TLR9 polymorphisms in CRC patients compared with the control groups highlight the role of these polymorphism in CRC development and cancer progression.
|
29883450 |
2018 |
|
Colorectal Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
TLR9 expression was decreased in hyperplastic and villous polyps from patients who developed CC.
|
22371291 |
2012 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
The results cast doubt on the usefulness of TLR9 agonist in treating colorectal cancer.
|
25546690 |
2014 |
|
Necrotizing Enterocolitis
|
0.210 |
Biomarker
|
disease |
BEFREE |
Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis.
|
19109197 |
2009 |
|
Anxiety
|
0.110 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate functional relevance of TLR9 in protecting stressed mammals from overreacting to traumatic experiences and suggest using oligonucleotide-mediated peripheral TLR9 activation to potentiate the innate immune system and prevent post-traumatic inflammation and anxiety.
|
22832815 |
2012 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, a possible association of TLR9 polymorphism C-1237T with asthma has been reported.
|
16164440 |
2005 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It was concluded that TLR9 and CD14 gene polymorphisms may contribute to an inherited predisposition to asthma in Tunisian children.
|
18312481 |
2008 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that TLR9 activation by CpG A suppresses IL-33-mediated AHR and airway inflammation through inhibition of ILC2s.
|
30914379 |
2019 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the on-treatment group, TLR1, TLR2, TLR6, and TLR9 expressions on PBMCs were significantly different between asthmatics and controls.
|
20072849 |
2010 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Asthmatics had significantly lower circulating HPC expressing TLR-2 and TLR-9 with a similar trend for TLR-4.
|
28252235 |
2017 |
|
Asthma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Polymorphisms in the identified chitin receptors, NOD2 and TLR9, predispose individuals to inflammatory conditions and dysregulated expression of chitinases and chitinase-like binding proteins, whose activity is essential to generate IL-10-inducing fungal chitin particles in vitro, have also been linked to inflammatory conditions and asthma.
|
24722226 |
2014 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic variations within human TLR9 have been reported to be associated with a range of immune-related diseases, such as asthma, systemic lupus erythematosus (SLE) and so on.
|
19130296 |
2009 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that 1) phenotype spread to the neo-allergen can be induced only within the first 8 h after a bronchial challenge with the first Ag (OVA); 2) Th2 differentiation of naive CD4(+) T cells occurs in bronchial lymph nodes; 3) trafficking of naive CD4(+) T cells to local lymph nodes and IL-4 produced by OVA-activated Th2 cells play essential roles in the differentiation of naive CD4(+) T cells to Th2 cells; and 4) suppression of the production of chemokines involved in the homing of naive CD4(+) T and Th2 cells to bronchial lymph nodes by a TLR9 agonist inhibited phenotype spread and abrogated the consequent development of experimental asthma.
|
15843591 |
2005 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma.
|
20623989 |
2010 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To study whether single nucleotide polymorphisms (SNPs) in CD14 and Toll-like receptor (TLR) 2, TLR4 and TLR9 genes are associated with asthma in adults, and whether these SNPs modify associations between country living and asthma.
|
19096003 |
2009 |